<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887429</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-202</org_study_id>
    <nct_id>NCT03887429</nct_id>
  </id_info>
  <brief_title>Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal</brief_title>
  <official_title>An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promentis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Promentis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or
      placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain
      from the use of cigarettes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2A, randomized, double-blinded, placebo-controlled, two-period
      crossover study to evaluate the effect of two doses of SXC-2023 on measures of impulsivity
      and inhibitory control, urge for cigarettes, and mood in non-treatment seeking smokers who
      are abstaining from smoking. The study consists of a screening period of up to 30 days, a 5
      day randomized double-blind treatment period, a 9 day washout period, followed by a second 5
      day randomized double-blind treatment period, with a safety follow-up period 7 days after the
      last dose of study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">July 9, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of SXC-2023.</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Endpoint assessed using the frequency of serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of SXC-2023 on Impulsivity, Measured Using Stop Signal Task.</measure>
    <time_frame>5 days</time_frame>
    <description>Stop Signal Reaction Time (SSRT) assesses the length of reaction time between a 'go' stimulus and a 'stop' stimulus at which the subject is able to inhibit their motor response 50% of the time. The scale is from 0-1500 milliseconds with a lower value showing reduced motor impulsivity. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment, and the change in subject scores was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of SXC-2023 on Risk Taking Behavior, as Measured Using Cambridge Gamblers Task - Delay Aversion Total.</measure>
    <time_frame>5 days</time_frame>
    <description>Cambridge Gamblers Task measures risk taking behavior using a score from -1 to 1, with a higher value showing increased impulsivity. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment and change in score assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of SXC-2023 on Abstinence Induced Mood, Assessed by Positive and Negative Affect Schedule.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Outcome to be measured using two scores ranging from 10-50, with a higher score indicating a more positive affect, and a lower score indicating a more negative affect. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes, Assessed by Questionnaire on Smoking Urges.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Outcome to be measured using a score ranging from 10-70, with a higher score indicating a higher urge for a cigarette. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes, Assessed by Cigarette Evaluation Questionnaire.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Outcome to be measured using five scores ranging from 1-7 and corresponding to &quot;Smoking Satisfaction,&quot; &quot;Psychological Reward,&quot; &quot;Aversion,&quot; &quot;Enjoyment of Respiratory Tract Sensations&quot; and &quot;Craving Reduction.&quot; A higher score indicates a greater intensity of the associated sensation. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes and Mood, Assessed by Cue Reactivity and Likert Assessment.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Outcome to be measured using two scores, the first ranging from 10-70, with a higher score indicating a stronger urge to smoke, and the second score ranging from 10-80, with a higher score indicating a more positive mood. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Levels of Glutathione (GSH) in Whole Blood Following 5 Days of Tobacco Abstinence.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Levels total and/or reduced of GSH in whole blood will be collected at baseline (prior to dosing on Day 1) and after 5 days of tobacco abstinence (after dosing on Day 5). Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Impulse Control Disorders</condition>
  <arm_group>
    <arm_group_label>SXC-2023 200 mg followed by placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by SXC-2023 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SXC-2023 800 mg followed by placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by SXC-2023 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SXC-2023</intervention_name>
    <description>SXC-2023 oral capsules</description>
    <arm_group_label>Placebo followed by SXC-2023 200 mg</arm_group_label>
    <arm_group_label>Placebo followed by SXC-2023 800 mg</arm_group_label>
    <arm_group_label>SXC-2023 200 mg followed by placebo</arm_group_label>
    <arm_group_label>SXC-2023 800 mg followed by placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Matching Placebo oral capsules</description>
    <arm_group_label>Placebo followed by SXC-2023 200 mg</arm_group_label>
    <arm_group_label>Placebo followed by SXC-2023 800 mg</arm_group_label>
    <arm_group_label>SXC-2023 200 mg followed by placebo</arm_group_label>
    <arm_group_label>SXC-2023 800 mg followed by placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult, female or male, 28-55 years of age, inclusive at screening.

          2. BMI ≥ 16.0 and ≤ 35.0 kg/m2 at screening.

          3. Has provided signed written informed consent and has willingness and ability to comply
             with all aspects of the protocol, including abstaining from the use of
             tobacco/nicotine products for two 5-day periods.

          4. Non-treatment seeking smokers regularly using tobacco with a FTND score ≥4 at
             screening and self-reported use of ≥10 cigarettes/day at screening.

          5. Has smoked for &gt;5 years at screening.

          6. Meets Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)
             criteria for tobacco use disorder.

          7. Must have a score ≥ 4 on the FTND and an expired-air CO level ≥10 ppm during initial
             screening and prior to first dose.

          8. For a female of childbearing potential: either be sexually inactive (abstinent as a
             life style) for 28 days prior to the first dosing and throughout the study or be using
             one of the following acceptable birth control methods:

               -  Oral contraceptives used for at least 3 months prior to the first dose.

               -  Non-hormone releasing intrauterine device for at least 3 months prior to the
                  first dose and with either a physical (e.g., condom, diaphragm, or other) or a
                  chemical (e.g., spermicide) barrier method from the time of screening and
                  throughout the study.

               -  Double physical barrier method (e.g., condom and diaphragm) from 14 days prior to
                  the first dose and throughout the study.

          9. Female of non-childbearing potential: must have undergone one of the following
             sterilization procedures, at least 6 months prior to the first dose:

               1. hysteroscopic sterilization;

               2. bilateral tubal ligation or bilateral salpingectomy;

               3. hysterectomy;

               4. bilateral oophorectomy; Or be postmenopausal with amenorrhea for at least 1 year
                  prior to the first dose with serum follicle stimulating hormone levels consistent
                  with postmenopausal status or have medically documented history of biological or
                  congenital sterility.

         10. Has not used Aricept 30 days prior to screening.

        Exclusion Criteria:

          1. Subject is mentally or legally incapacitated or has significant emotional problems or
             clinically significant abnormality at the time of the screening visit or expected
             during the conduct of the study.

          2. Subject suffered a concussion 6 months or less prior to screening.

          3. Females who are pregnant or breastfeeding.

          4. Positive for active hepatitis, human immunodeficiency virus (HIV), coagulopathy, or
             hepatic illness.

          5. Use of Selective Serotonin or Norepinephrine Reuptake Inhibitors for psychiatric
             illness (e.g. depression, anxiety, etc.), unless subject has been on a stable dose for
             at least 30 days prior to screening.

          6. Use of antipsychotics or use of antiepileptics within 30 days prior to screening.

          7. Use of NAC within 30 days prior to screening.

          8. Use of Chantix or related smoking cessation medications (e.g., NicoDerm patch,
             Nicorette gum, etc) within 30 days prior to the first dose.

          9. Use of sulfasalazine (Azulfidine®) within 30 days prior to the first dose.

         10. DSM-5 criteria for alcohol/substance use disorder (except for tobacco use disorder).

         11. History or presence of clinically significant psychiatric condition (except for
             tobacco use disorder) or disease in the opinion of the PI or designee.

         12. History of any illness that, in the opinion of the PI or designee, might confound the
             results of the study or poses an additional risk to the subject by their participation
             in the study.

         13. History of seizures.

         14. Any history of psychiatric hospitalization in the past year.

         15. Currently participating in a clinical study.

         16. Previously participated in any Phase 1 Promentis studies or dosed in this Phase 2A
             study.

         17. FTND score &lt;4 and expelled CO levels &lt;10 ppm at screening and prior to first dose.

         18. Any clinically significant laboratory, ECG and/or vital sign abnormalities at
             screening.

         19. Unable to read/understand/speak English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion Inc.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <results_first_submitted>June 8, 2020</results_first_submitted>
  <results_first_submitted_qc>June 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2020</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SXC-2023</keyword>
  <keyword>Cognitive Control</keyword>
  <keyword>Impulsivity</keyword>
  <keyword>Delay Aversion</keyword>
  <keyword>Top Down Processing</keyword>
  <keyword>Behavioral Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03887429/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SXC-2023 200 mg Followed by Placebo</title>
          <description>SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="P2">
          <title>Placebo Followed by SXC-2023 200 mg</title>
          <description>Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="P3">
          <title>SXC-2023 800 mg Followed by Placebo</title>
          <description>SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="P4">
          <title>Placebo Followed by SXC-2023 800 mg</title>
          <description>Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed First Intervention (5 Days)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Washout (9 Days)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Second Intervention (5 Days)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SXC-2023 200 mg Followed by Placebo</title>
          <description>SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="B2">
          <title>Placebo Followed by SXC-2023 200 mg</title>
          <description>Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="B3">
          <title>SXC-2023 800 mg Followed by Placebo</title>
          <description>SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="B4">
          <title>Placebo Followed by SXC-2023 800 mg</title>
          <description>Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
SXC-2023: SXC-2023 oral capsules
Placebos: Matching Placebo oral capsules</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="7.1"/>
                    <measurement group_id="B2" value="44" spread="8.5"/>
                    <measurement group_id="B3" value="39" spread="7.7"/>
                    <measurement group_id="B4" value="41" spread="9.5"/>
                    <measurement group_id="B5" value="42" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of SXC-2023.</title>
        <description>Endpoint assessed using the frequency of serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.</description>
        <time_frame>Up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>During 200 mg SXC-2023 Treatment</title>
            <description>AEs observed during treatment with SXC-2023 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>During 800 mg SXC-2023 Treatment</title>
            <description>AEs observed during treatment with SXC-2023 800 mg.</description>
          </group>
          <group group_id="O3">
            <title>During Placebo Treatment</title>
            <description>AEs observed during treatment with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of SXC-2023.</title>
          <description>Endpoint assessed using the frequency of serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to study discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs judged to be related to study drug.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Activity of SXC-2023 on Impulsivity, Measured Using Stop Signal Task.</title>
        <description>Stop Signal Reaction Time (SSRT) assesses the length of reaction time between a 'go' stimulus and a 'stop' stimulus at which the subject is able to inhibit their motor response 50% of the time. The scale is from 0-1500 milliseconds with a lower value showing reduced motor impulsivity. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment, and the change in subject scores was assessed.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SXC-2023 200mg</title>
            <description>Change in subjects treated with 200 mg SXC-2023 for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>SXC-2023 800mg</title>
            <description>Change in subjects treated with 800 mg SXC-2023 for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Change in subjects treated with Placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity of SXC-2023 on Impulsivity, Measured Using Stop Signal Task.</title>
          <description>Stop Signal Reaction Time (SSRT) assesses the length of reaction time between a 'go' stimulus and a 'stop' stimulus at which the subject is able to inhibit their motor response 50% of the time. The scale is from 0-1500 milliseconds with a lower value showing reduced motor impulsivity. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment, and the change in subject scores was assessed.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6901" spread="6.7368"/>
                    <measurement group_id="O2" value="-1.757" spread="6.8491"/>
                    <measurement group_id="O3" value="3.956" spread="3.9661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that treatment with SXC-2023 would reduce impulsivity as measured by SSRT in chronic cigarette smokers abstaining from nicotine for 5 days.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=.009</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Activity of SXC-2023 on Risk Taking Behavior, as Measured Using Cambridge Gamblers Task - Delay Aversion Total.</title>
        <description>Cambridge Gamblers Task measures risk taking behavior using a score from -1 to 1, with a higher value showing increased impulsivity. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment and change in score assessed.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SXC-2023 200mg</title>
            <description>Change in subjects treated with 200 mg SXC-2023 for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>SXC-2023 800mg</title>
            <description>Change in subjects treated with 800 mg SXC-2023 for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Change in subjects treated with Placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity of SXC-2023 on Risk Taking Behavior, as Measured Using Cambridge Gamblers Task - Delay Aversion Total.</title>
          <description>Cambridge Gamblers Task measures risk taking behavior using a score from -1 to 1, with a higher value showing increased impulsivity. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment and change in score assessed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03236" spread=".02652"/>
                    <measurement group_id="O2" value=".01358" spread=".02655"/>
                    <measurement group_id="O3" value=".03931" spread=".01569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that 5 days of nicotine abstinence in chronic cigarette smokers would result in increased risk taking behavior as measured using DAVT in subjects receiving placebo as treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=.015</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that 5 days of nicotine abstinence in chronic cigarette smokers would not result in increased risk taking behavior as measured using DAVT in subjects treated with SXC-2023.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;.1</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Activity of SXC-2023 on Abstinence Induced Mood, Assessed by Positive and Negative Affect Schedule.</title>
        <description>Outcome to be measured using two scores ranging from 10-50, with a higher score indicating a more positive affect, and a lower score indicating a more negative affect. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
        <time_frame>Up to 5 days.</time_frame>
        <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg SXC-2023 or Placebo QD</title>
            <description>Change in Positive and Negative affect in subjects treated with 200 mg SXC-2023 or placebo for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>800 mg SXC-2023 or Placebo QD</title>
            <description>Change in Positive and Negative affect in subjects treated with 800 mg SXC-2023 or placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity of SXC-2023 on Abstinence Induced Mood, Assessed by Positive and Negative Affect Schedule.</title>
          <description>Outcome to be measured using two scores ranging from 10-50, with a higher score indicating a more positive affect, and a lower score indicating a more negative affect. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
          <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SXC-2023 Change in Positive Aspect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="8.2"/>
                    <measurement group_id="O2" value="2.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo Change in Positive Aspect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="7.43"/>
                    <measurement group_id="O2" value="3.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 Change in Negative Aspect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.9" spread="5.01"/>
                    <measurement group_id="O2" value="-1.2" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo Change in Negative Aspect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.7" spread="3.93"/>
                    <measurement group_id="O2" value=".1" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes, Assessed by Questionnaire on Smoking Urges.</title>
        <description>Outcome to be measured using a score ranging from 10-70, with a higher score indicating a higher urge for a cigarette. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
        <time_frame>Up to 5 days.</time_frame>
        <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 200 mg SXC-2023 or placebo for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>800 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 800 mg SXC-2023 or placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes, Assessed by Questionnaire on Smoking Urges.</title>
          <description>Outcome to be measured using a score ranging from 10-70, with a higher score indicating a higher urge for a cigarette. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
          <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SXC-2023 Change in Anticipation of Pleasure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.3" spread="1.155"/>
                    <measurement group_id="O2" value=".64" spread="1.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Anticipation of Pleasure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.04" spread="1.1236"/>
                    <measurement group_id="O2" value=".17" spread=".848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Anticipation of Relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".14" spread="1.201"/>
                    <measurement group_id="O2" value=".21" spread="1.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Anticipation of Relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.06" spread=".946"/>
                    <measurement group_id="O2" value=".46" spread=".794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes, Assessed by Cigarette Evaluation Questionnaire.</title>
        <description>Outcome to be measured using five scores ranging from 1-7 and corresponding to &quot;Smoking Satisfaction,&quot; &quot;Psychological Reward,&quot; &quot;Aversion,&quot; &quot;Enjoyment of Respiratory Tract Sensations&quot; and &quot;Craving Reduction.&quot; A higher score indicates a greater intensity of the associated sensation. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
        <time_frame>Up to 5 days.</time_frame>
        <population>Complications with application of scales prevented collection of data from the majority of subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 200 mg SXC-2023 or placebo for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>800 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 800 mg SXC-2023 or placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes, Assessed by Cigarette Evaluation Questionnaire.</title>
          <description>Outcome to be measured using five scores ranging from 1-7 and corresponding to &quot;Smoking Satisfaction,&quot; &quot;Psychological Reward,&quot; &quot;Aversion,&quot; &quot;Enjoyment of Respiratory Tract Sensations&quot; and &quot;Craving Reduction.&quot; A higher score indicates a greater intensity of the associated sensation. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
          <population>Complications with application of scales prevented collection of data from the majority of subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SXC-2023 change in Satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".1" spread="1.28"/>
                    <measurement group_id="O2" value=".4" spread=".51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".3" spread=".33"/>
                    <measurement group_id="O2" value="-.2" spread=".69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Psychological reward</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".16" spread="1.315"/>
                    <measurement group_id="O2" value=".33" spread=".808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Psychological reward</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8" spread=".693"/>
                    <measurement group_id="O2" value="-.2" spread="1.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Aversion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7" spread="1.396"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Aversion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value=".63" spread=".946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Enjoyment of Sensation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.58"/>
                    <measurement group_id="O2" value="1.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Enjoyment of Sensation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value=".8" spread=".96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Craving Reduction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.4" spread="1.14"/>
                    <measurement group_id="O2" value=".3" spread=".58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Craving Reduction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.7" spread="2.08"/>
                    <measurement group_id="O2" value="0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes and Mood, Assessed by Cue Reactivity and Likert Assessment.</title>
        <description>Outcome to be measured using two scores, the first ranging from 10-70, with a higher score indicating a stronger urge to smoke, and the second score ranging from 10-80, with a higher score indicating a more positive mood. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
        <time_frame>Up to 5 days.</time_frame>
        <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 200 mg SXC-2023 or placebo for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>800 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 800 mg SXC-2023 or placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity of SXC-2023 on Measures of Abstinence Induced Urge for Cigarettes and Mood, Assessed by Cue Reactivity and Likert Assessment.</title>
          <description>Outcome to be measured using two scores, the first ranging from 10-70, with a higher score indicating a stronger urge to smoke, and the second score ranging from 10-80, with a higher score indicating a more positive mood. Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
          <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SXC-2023 change in Neutral Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".353" spread="1.7932"/>
                    <measurement group_id="O2" value="-.052" spread="1.8934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Neutral Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.142" spread="1.5071"/>
                    <measurement group_id="O2" value="-.173" spread="1.5458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Neutral Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.058" spread="1.3775"/>
                    <measurement group_id="O2" value="1.667" spread="1.6004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Neutral Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".602" spread="1.7237"/>
                    <measurement group_id="O2" value="1.192" spread="1.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Positive Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".5" spread="1.922"/>
                    <measurement group_id="O2" value=".12" spread="1.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Positive Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.12" spread="1.543"/>
                    <measurement group_id="O2" value="-.04" spread="1.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Positive Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.509"/>
                    <measurement group_id="O2" value="1.35" spread="2.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Positive Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".73" spread="1.666"/>
                    <measurement group_id="O2" value="1.38" spread="1.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Smoking Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".39" spread="2.105"/>
                    <measurement group_id="O2" value="-.23" spread="1.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Smoking Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.65" spread="1.864"/>
                    <measurement group_id="O2" value="-.27" spread="1.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SXC-2023 change in Smoking Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".42" spread="1.352"/>
                    <measurement group_id="O2" value="1.65" spread="1.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in Smoking Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".88" spread="1.431"/>
                    <measurement group_id="O2" value="1" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Levels of Glutathione (GSH) in Whole Blood Following 5 Days of Tobacco Abstinence.</title>
        <description>Levels total and/or reduced of GSH in whole blood will be collected at baseline (prior to dosing on Day 1) and after 5 days of tobacco abstinence (after dosing on Day 5). Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
        <time_frame>Up to 5 days.</time_frame>
        <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 200 mg SXC-2023 or placebo for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>800 mg SXC-2023 or Placebo QD</title>
            <description>Change in subjects treated with 800 mg SXC-2023 or placebo for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Glutathione (GSH) in Whole Blood Following 5 Days of Tobacco Abstinence.</title>
          <description>Levels total and/or reduced of GSH in whole blood will be collected at baseline (prior to dosing on Day 1) and after 5 days of tobacco abstinence (after dosing on Day 5). Subject scores were collected pre-dose on day 1 of treatment and post-dose on day 5 of treatment.</description>
          <population>Subjects who did not complete treatment with both placebo and SXC-2023 were excluded from analysis.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SXC-2023 change in GSH concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.45" spread="23.318"/>
                    <measurement group_id="O2" value="-20.6" spread="73.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo change in GSH concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.13" spread="21.826"/>
                    <measurement group_id="O2" value="-5.12" spread="23.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 day treatment period, and following 9 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>During 200 mg SXC-2023 Treatment</title>
          <description>AEs observed during treatment with SXC-2023 200 mg.</description>
        </group>
        <group group_id="E2">
          <title>During 800 mg SXC-2023 Treatment</title>
          <description>AEs observed during treatment with SXC-2023 800 mg.</description>
        </group>
        <group group_id="E3">
          <title>During Placebo Treatment</title>
          <description>AEs observed during treatment with Placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Defecation Urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chad Beyer</name_or_title>
      <organization>Promentis Pharmaceuticals</organization>
      <phone>(414) 238 2992</phone>
      <email>cbeyer@promentispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

